Abiraterone Teva is indicated:1. in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.2. For the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).